Ribavirin is not effective against Crimean-Congo hemorrhagic fever: Observations from the Turkish experience

International Journal of Infectious Diseases

Volumn 17, Issue 10, 2013, Pages

  Ceylan, Bahadir ^a   Calica, Aylin ^a   Ak, Oznur ^a   Akkoyunlu, Yasemin ^a   Turhan, Vedat ^a  

^a BEZMIALEM VAKIF UNIVERSITY   (Turkey)

Author keywords

Crimean Congo hemorrhagic fever; Ribavirin

Indexed keywords

RIBAVIRIN;

CLIMATE CHANGE; CRIMEAN CONGO HEMORRHAGIC FEVER; DISEASE COURSE; DRUG EFFICACY; GENOTOXICITY; HUMAN; HYPOXEMIA; MORTALITY; MUTAGENIC ACTIVITY; MUTAGENICITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEVERE ACUTE RESPIRATORY SYNDROME; SHORT SURVEY; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; TURKEY (REPUBLIC); UNSPECIFIED SIDE EFFECT; VIRUS LOAD; VIRUS REPLICATION;

CRIMEAN-CONGO HEMORRHAGIC FEVER; RIBAVIRIN;

ANTIVIRAL AGENTS; HEMORRHAGIC FEVER VIRUS, CRIMEAN-CONGO; HEMORRHAGIC FEVER, CRIMEAN; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RIBAVIRIN; TREATMENT FAILURE; TURKEY;

EID: 84883790597     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2013.02.030     Document Type: Short Survey

References (23)

1. Ergonul O. Crimean-Congo haemorrhagic fever virus: new outbreaks, new discoveries. Curr Opin Virol 2012, 2:215-220.
2. Doganci L. New insights on the bleeding disorders in CCHF. J Infect 2007, 55:379-381.
3. Chen J.P., Cosgriff T.M. Haemorrhagic fever virus induced changes in hemostasis and vascular biology. Blood Coagul Fibrinolysis 2000, 11:461-483.
4. Peters C.J., Zaki S.R. Role of the endothelium in viral hemorrhagic fevers. Crit Care Med 2002, 30:268-273.
5. Ergonul O., Tuncbilek S., Baykam N., Celikbas A., Dokuzoguz B. Evaluation of serum levels of interleukin (IL)-6, IL-10, and tumor necrosis factor-alpha in patients with Crimean-Congo haemorrhagic fever. J Infect Dis 2006, 193:941-944.
6. Keshtkar-Jahromi M., Kuhn J.H., Christova I., Bradfute S.B., Jahrling P.B., Bavari S. Crimean-Congo haemorrhagic fever: current and future prospects of vaccines and therapies. Antiviral Res 2011, 90:85-92.
7. Mardani M., Keshtkar-Jahromi M., Holakouie-Naieni K., Zeinali M. The efficacy of oral ribavirin in the treatment of Crimean-Congo hemorrhagic fever in Iran. Clin Infect Dis 2003, 36:1613-1618.
8. Izadi S., Salehi M. Evaluation of the efficacy of ribavirin therapy on survival of Crimean-Congo haemorrhagic fever patients: a case-control study. Jpn J Infect Dis 2009, 62:11-15.
9. Ozkurt Z., Kiki I., Erol S., Erdem F., Yilmaz N., Parlak M., et al. Crimean-Congo haemorrhagic fever in Eastern Turkey: clinical features, risk factors and efficacy of ribavirin therapy. J Infect 2006, 52:207-215.
10. Elaldi N., Bodur H., Ascioglu S., Celicbas A., Ozkurt Z., Vahaboglu H., et al. Efficacy of oral ribavirin treatment in Crimean-Congo haemorrhagic fever: a quasi-experimental study from Turkey. J Infect 2009, 58:238-244.
11. Bodur H., Erbay A., Akinci E., Öngürü P., Bayazit N., Eren S.S., et al. Effect of ribavirin treatment on the viral load and disease progression in Crimean-Congo hemorrhagic fever. Int J Infect Dis 2011, 15:e44-e47.
12. Tasdelen-Fisgin N., Ergonul O., Doganci L., Tulek N. The role of ribavirin in the therapy of Crimean-Congo haemorrhagic fever: early use is promising. Eur J Clin Microbiol Infect Dis 2009, 28:929-933.
13. Koksal I., Yilmaz G., Aksoy F., Aydin H., Yavuz I., Iskender S., et al. The efficacy of ribavirin in the treatment of Crimean-Congo haemorrhagic fever in Eastern Black Sea region in Turkey. J Clin Virol 2010, 47:65-68.
14. Ergonul O. Crimean-Congo haemorrhagic fever. Lancet Infect Dis 2006, 6:203-214.
15. Watts D.M., Ussery M.A., Nash D., Peters C.J. Inhibition of Crimean-Congo hemorrhagic fever viral infectivity yields in vitro by ribavirin. Am J Trop Med Hyg 1989, 41:581-585.
16. Duygu F., Kaya T., Baysan P. Re-evaluation of 400 Crimean-Congo hemorrhagic fever cases in an endemic area: is ribavirin treatment suitable?. Vector Borne Zoonotic Dis 2011, 12:812-816.
17. Özcan MM, Elaldi N, Engin A, Korukluoǧlu G, Dökmetaş I, Bakir M, et al. Oral ribavirin treatment of Crimean-Congo haemorrhagic fever: Kirim-Kongo hemorajik ateşinde oral ribavirin tedavisi: evaluation of 850 patients. 3rd Turkish EKMUD Congress, May 12-16, 2010. Ankara, Turkey. Congress Book; 2010, p. 204.
18. Duh D., Saksida A., Petrovec M., Ahmeti S., Dedushaj I., Panning M., et al. Viral load as predictor of Crimean-Congo hemorrhagic fever outcome. Emerg Infect Dis 2007, 13:1769-1772.
19. Yilmaz G.R., Buzgan T., Irmak H., Safran A., Uzun R., Cevik M.A., et al. The epidemiology of Crimean-Congo hemorrhagic fever in Turkey, 2002-2007. Int J Infect Dis 2009, 13:380-386.
20. Chiou H.E., Liu C.L., Buttrey M.J., Kuo H.P., Liu H.W., Kuo H.T., et al. Adverse effects of ribavirin and outcome in severe acute respiratory syndrome: experience in two medical centers. Chest 2005, 128:263-272.
21. Tatar A., Ozkurt Z., Kiki I. Genotoxic effect of ribavirin in patients with Crimean-Congo hemorrhagic fever. Jpn J Infect Dis 2005, 58:313-315.
22. D'Souza U.J., Narayana K. Mechanism of cytotoxicity of ribavirin in the rat bone marrow and testis. Indian J Physiol Pharmacol 2002, 46:468-474.
23. Narayana K., D'Souza U.J., Seetharama Rao K.P. Ribavirin-induced sperm shape abnormalities in Wistar rat. Mutat Res 2002, 513:193-196.